Whole-Genome Sequence Analysis of Candida glabrata Isolates from a Patient with Persistent Fungemia and Determination of the Molecular Mechanisms of Multidrug Resistance

Whole-genome sequencing (WGS) was used to determine the molecular mechanisms of multidrug resistance for 10 serial Candida glabrata bloodstream isolates obtained from a neutropenic patient during 82 days of amphotericin B (AMB) or echinocandin therapy. For WGS, a library was prepared and sequenced using a Nextera DNA Flex Kit (Illumina) and the MiseqDx (Illumina) instrument. All isolates harbored the same Msh2p substitution, V239L, associated with multilocus sequence type 7 and a Pdr1p substitution, L825P, that caused azole resistance. Of six isolates with increased AMB MICs (≥2 mg/L), three harboring the Erg6p A158fs mutation had AMB MICs ≥ 8 mg/L, and three harboring the Erg6p R314K, Erg3p G236D, or Erg3p F226fs mutation had AMB MICs of 2–3 mg/L. Four isolates harboring the Erg6p A158fs or R314K mutation had fluconazole MICs of 4–8 mg/L while the remaining six had fluconazole MICs ≥ 256 mg/L. Two isolates with micafungin MICs > 8 mg/L harbored Fks2p (I661_L662insF) and Fks1p (C499fs) mutations, while six isolates with micafungin MICs of 0.25–2 mg/L harbored an Fks2p K1357E substitution. Using WGS, we detected novel mechanisms of AMB and echinocandin resistance; we explored mechanisms that may explain the complex relationship between AMB and azole resistance.

[1]  Yong Jun Kwon,et al.  Dynamics and Predictors of Mortality Due to Candidemia Caused by Different Candida Species: Comparison of Intensive Care Unit-Associated Candidemia (ICUAC) and Non-ICUAC , 2021, Journal of fungi.

[2]  V. S. Parmar,et al.  Antimycotic Drugs and their Mechanisms of Resistance to Candida Species. , 2021, Current drug targets.

[3]  Mina Kim,et al.  Fluconazole-Resistant Candida glabrata Bloodstream Isolates, South Korea, 2008–2018 , 2021, Emerging infectious diseases.

[4]  T. Gabaldón,et al.  The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens , 2020, Journal of fungi.

[5]  K. Cronin,et al.  Antifungal Susceptibility of Clinical Yeast Isolates from a Large Canadian Reference Laboratory and Application of Whole-Genome Sequence Analysis To Elucidate Mechanisms of Acquired Resistance , 2020, Antimicrobial Agents and Chemotherapy.

[6]  W. S. Moye-Rowley,et al.  Evidence that Ergosterol Biosynthesis Modulates Activity of the Pdr1 Transcription Factor in Candida glabrata , 2019, mBio.

[7]  M. Kostrzewa,et al.  Low Level of Antifungal Resistance in Iranian Isolates of Candida glabrata Recovered from Blood Samples in a Multicenter Study from 2015 to 2018 and Potential Prognostic Values of Genotyping and Sequencing of PDR1 , 2019, Antimicrobial Agents and Chemotherapy.

[8]  Ronald N. Jones,et al.  Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016 , 2019, Open forum infectious diseases.

[9]  C. Fairhead,et al.  Genome Comparisons of Candida glabrata Serial Clinical Isolates Reveal Patterns of Genetic Variation in Infecting Clonal Populations , 2019, Front. Microbiol..

[10]  Yong Jun Kwon,et al.  Candida auris Clinical Isolates from South Korea: Identification, Antifungal Susceptibility, and Genotyping , 2019, Journal of Clinical Microbiology.

[11]  Luis V. Santana-Quintero,et al.  In‐depth comparative analysis of Illumina® MiSeq run metrics: Development of a wet‐lab quality assessment tool , 2019, Molecular ecology resources.

[12]  Erika Shor,et al.  Novel FKS1 and FKS2 modifications in a high-level echinocandin resistant clinical isolate of Candida glabrata , 2019, Emerging microbes & infections.

[13]  S. Kelly,et al.  ERG6 and ERG2 Are Major Targets Conferring Reduced Susceptibility to Amphotericin B in Clinical Candida glabrata Isolates in Kuwait , 2018, Antimicrobial Agents and Chemotherapy.

[14]  P. Escribano,et al.  Low and constant micafungin concentrations may be sufficient to lead to resistance mutations in FKS2 gene of Candida glabrata. , 2018, Medical mycology.

[15]  Mina Kim,et al.  Multilocus Sequence Typing (MLST) Genotypes of Candida glabrata Bloodstream Isolates in Korea: Association With Antifungal Resistance, Mutations in Mismatch Repair Gene (Msh2), and Clinical Outcomes , 2018, Front. Microbiol..

[16]  D. Marriott,et al.  Whole Genome Sequencing of Australian Candida glabrata Isolates Reveals Genetic Diversity and Novel Sequence Types , 2018, Front. Microbiol..

[17]  P. Escribano,et al.  Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates , 2018, Antimicrobial Agents and Chemotherapy.

[18]  C. Fairhead,et al.  Patterns of Genomic Variation in the Opportunistic Pathogen Candida glabrata Suggest the Existence of Mating and a Secondary Association with Humans , 2018, Current Biology.

[19]  P. Le Pape,et al.  Molecular basis of antifungal drug resistance in yeasts. , 2017, International journal of antimicrobial agents.

[20]  S. Suh,et al.  Diversity of clinical isolates of Aspergillus terreus in antifungal susceptibilities, genotypes and virulence in Galleria mellonella model: Comparison between respiratory and ear isolates , 2017, PloS one.

[21]  M. Arendrup,et al.  Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment , 2017, The Journal of infectious diseases.

[22]  S. Bates,et al.  Galleria mellonella as a host model to study Candida glabrata virulence and antifungal efficacy , 2017, Virulence.

[23]  Christina A. Cuomo,et al.  Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  Marek S. Skrzypek,et al.  The Candida Genome Database (CGD): incorporation of Assembly 22, systematic identifiers and visualization of high throughput sequencing data , 2016, Nucleic Acids Res..

[25]  B. Alexander,et al.  Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance , 2016, Nature Communications.

[26]  C. Clancy,et al.  Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection , 2015, Antimicrobial Agents and Chemotherapy.

[27]  M. Arendrup,et al.  Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations. , 2015, The Journal of antimicrobial chemotherapy.

[28]  H. Sung,et al.  Emergence of multiple resistance profiles involving azoles, echinocandins and amphotericin B in Candida glabrata isolates from a neutropenia patient with prolonged fungaemia. , 2014, The Journal of antimicrobial chemotherapy.

[29]  D. Kontoyiannis,et al.  Drug-Resistant Candida glabrata Infection in Cancer Patients , 2014, Emerging infectious diseases.

[30]  W. Schaffner,et al.  Role of FKS Mutations in Candida glabrata: MIC Values, Echinocandin Resistance, and Multidrug Resistance , 2014, Antimicrobial Agents and Chemotherapy.

[31]  E. Mellado,et al.  Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis virulence in the non-conventional host Galleria mellonella , 2014, Virulence.

[32]  F. Queiroz-Telles,et al.  Breakthrough Candidemia Due to Multidrug-Resistant Candida glabrata during Prophylaxis with a Low Dose of Micafungin , 2014, Antimicrobial Agents and Chemotherapy.

[33]  S. Andreoni,et al.  Antifungal resistance does not necessarily affect Candida glabrata fitness , 2014, Journal of chemotherapy.

[34]  M. Henriques,et al.  Candida glabrata: a review of its features and resistance , 2013, European Journal of Clinical Microbiology & Infectious Diseases.

[35]  Ronald N. Jones,et al.  Frequency of fks Mutations among Candida glabrata Isolates from a 10-Year Global Collection of Bloodstream Infection Isolates , 2013, Antimicrobial Agents and Chemotherapy.

[36]  M. Castanheira,et al.  Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  D. Kelly,et al.  Two Clinical Isolates of Candida glabrata Exhibiting Reduced Sensitivity to Amphotericin B Both Harbor Mutations in ERG2 , 2012, Antimicrobial Agents and Chemotherapy.

[38]  J. Heitman,et al.  Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata , 2012, PLoS pathogens.

[39]  Jong-Hee Shin,et al.  First Three Reported Cases of Nosocomial Fungemia Caused by Candida auris , 2011, Journal of Clinical Microbiology.

[40]  M. Arendrup Epidemiology of invasive candidiasis , 2010, Current opinion in critical care.

[41]  D. Kelly,et al.  Identification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans , 2010, Antimicrobial Agents and Chemotherapy.

[42]  D. Kelly,et al.  A Clinical Isolate of Candida albicans with Mutations in ERG11 (Encoding Sterol 14α-Demethylase) and ERG5 (Encoding C22 Desaturase) Is Cross Resistant to Azoles and Amphotericin B , 2010, Antimicrobial Agents and Chemotherapy.

[43]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[44]  C. Hennequin,et al.  Acquisition of Flucytosine, Azole, and Caspofungin Resistance in Candida glabrata Bloodstream Isolates Serially Obtained from a Hematopoietic Stem Cell Transplant Recipient , 2009, Antimicrobial Agents and Chemotherapy.

[45]  B. Dujon,et al.  Genomic polymorphism in the population of Candida glabrata: gene copy-number variation and chromosomal translocations. , 2009, Fungal genetics and biology : FG & B.

[46]  J. Bouchara,et al.  A Nonsense Mutation in the ERG6 Gene Leads to Reduced Susceptibility to Polyenes in a Clinical Isolate of Candida glabrata , 2008, Antimicrobial Agents and Chemotherapy.

[47]  K. Marr Fungal infections in hematopoietic stem cell transplant recipients. , 2008, Medical mycology.

[48]  C. Hennequin,et al.  Reduced Susceptibility to Polyenes Associated with a Missense Mutation in the ERG6 Gene in a Clinical Isolate of Candida glabrata with Pseudohyphal Growth , 2006, Antimicrobial Agents and Chemotherapy.

[49]  M. Falagas,et al.  Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies , 2006, European Journal of Clinical Microbiology and Infectious Diseases.

[50]  M. Arendrup,et al.  Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  S. A. Parent,et al.  Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates , 2005, Antimicrobial Agents and Chemotherapy.

[52]  M. Maiden,et al.  Optimization and Validation of Multilocus Sequence Typing for Candida albicans , 2003, Journal of Clinical Microbiology.

[53]  D. Sanglard,et al.  Candida albicans Mutations in the Ergosterol Biosynthetic Pathway and Resistance to Several Antifungal Agents , 2003, Antimicrobial Agents and Chemotherapy.

[54]  S. Kohlwein,et al.  Biochemical characterization and subcellular localization of the sterol C‐24(28) reductase, Erg4p, from the yeast Saccharomyces cerevisiae , 2000, FEBS letters.

[55]  T. C. White,et al.  Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. , 2000, The Journal of infectious diseases.

[56]  D. Kelly,et al.  Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients , 1996, The Lancet.

[57]  J. Swartz,et al.  Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility , 1995, Antimicrobial agents and chemotherapy.

[58]  Sudhir Kumar,et al.  MEGA: Molecular Evolutionary Genetics Analysis software for microcomputers , 1994, Comput. Appl. Biosci..